Zhang et al. examined the ability of ExVs derived from glycosyl-phosphatidylinositol-anchored IL-2 (GPI-IL-2) gene-modified bladder cancer cells to increase antitumor responses. The gene discussed is IL2; the disease is urinary bladder cancer.